stockrow
Saturday 7 November 2026
Export MCRB’s income statement to Excel — free account
Seres Therapeutics, Inc.
MCRB Healthcare Biotechnology
Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- −273.6%
- Free cash flow
- −576.7%
Quarter to September 2026, against a year earlier
1.98
0.11
−5.26%
Follow MCRB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
22.21 | 0.00 | 0.00 | 0.00 |
P/S ratio |
89.49 | 55.89 | 40.67 | 15.74 | |
P/FCF ratio |
122.63 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.96) | (5.20) | (3.42) | (3.19) | |
P/B ratio |
2.98 | 3.21 | 2.22 | 1.57 | |
Price to Tangible BV |
2.98 | 3.21 | 2.22 | 1.57 | |
EV/Sales |
128.00 | 103.66 | 86.82 | 55.72 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
168.80 | (3.74) | (3.19) | (1.85) | |
EV/FCF |
175.40 | (3.74) | (3.19) | (1.86) | |
Quick Ratio |
2.40 | 1.55 | 2.04 | 1.45 | |
Current Ratio |
2.56 | 1.65 | 2.11 | 1.65 | |
Net Debt/EBITDA |
2.48 | 1.48 | 0.76 | 1.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.02 | 0.02 | |
Operating CF/Net income |
0.96 | 0.82 | (4.89) | 0.64 | |
Capex/Depreciation |
0.19 | 0.00 | 0.02 | 0.11 | |
Research and Development Expense of Revenue |
2,667.58% | 3,685.75% | 1,241.98% | 943.00% | |
Selling, General and Administrative Expense of Revenue |
1,721.23% | 2,254.19% | 959.38% | 918.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
730.37% | 493.30% | 236.28% | 313.49% | |
Graham Net Nets |
(0.34) | (0.70) | (0.32) | (0.30) | |
Graham Number |
8.67 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
4.50% | (58.29%) | (30.80%) | (149.30%) | |
Free Cash Flow Yield |
0.82% | (49.64%) | (66.93%) | (190.50%) | |
Revenue per Share |
0.05 | 0.04 | 0.08 | 0.06 | |
Operating CF per Share |
(1.66) | (1.71) | (2.31) | (1.05) | |
Capex per Share |
0.02 | 0.00 | 0.00 | 0.01 | |
Free Cash Flow per Share |
(1.64) | (1.71) | (2.31) | (1.04) | |
Cash per Share |
5.17 | 3.11 | 1.61 | 1.76 | |
Shareholders Equity per Share |
4.99 | 2.77 | 3.56 | 2.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.99 | 2.77 | 3.56 | 2.14 | |
Free Cash Flow |
(14.53) | (16.36) | (22.38) | (10.42) | |
Working Capital |
30.05 | 12.49 | 22.32 | 13.53 | |
Capital Expenditures |
0.18 | — | 0.01 | 0.05 | |
Net Current Asset Value |
(44.60) | (59.28) | (24.71) | (10.11) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.41) | 0.00 | (0.02) | (0.09) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.29 | 1.50 | 13.08 | 6.73 | |
Average Payables |
2.88 | 2.25 | 1.69 | 1.57 | |
Average Assets |
139.00 | 140.90 | 122.69 | 104.68 | |
Average Common Equity |
29.00 | 38.48 | 33.74 | 32.53 |
Columns are period end dates · fundamentals updated 6 Nov 2026